Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
Cancer Medicine ( IF 2.9 ) Pub Date : 2020-03-26 , DOI: 10.1002/cam4.3007
Mateusz Jobczyk _{1,

2} , Konrad Stawiski ₃ , Wojciech Fendler _{3,

4} , Waldemar Różański ₁

Affiliation

Brief Description: The results demonstrate that the European Organisation for Research and Treatment of Cancer (EORTC) scale provides the best recurrence and progression prediction in comparison with European Association of Urology (EAU) and Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk scores among a mixed population of patients with non–muscle‐invasive bladder who were treated with, or without, Bacillus Calmette‐Guerin (BCG) and without any immediate postoperative chemotherapy. The study highlights the role of tumor diameter and extent in transition prediction.

中文翻译：

EORTC、CUETO 和 EAU 风险分层在预测初始非肌层浸润性膀胱癌 (NMIBC) 患者复发、进展和死亡方面的验证：队列分析。

简要说明：结果表明，与欧洲泌尿外科协会 (EAU) 和西班牙泌尿肿瘤俱乐部 (CUETO) 风险评分相比，欧洲癌症研究与治疗组织 (EORTC) 量表提供了最佳的复发和进展预测。一组患有非肌层浸润性膀胱的患者，他们接受或不接受卡介苗（BCG）治疗，且术后未立即进行化疗。该研究强调了肿瘤直径和范围在转变预测中的作用。

更新日期：2020-03-26

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11